Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

[1]  Sotorasib. , 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  M. Vanoni,et al.  Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas , 2020, Molecular Cancer Therapeutics.

[3]  S. Park,et al.  A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations , 2020, Clinical Cancer Research.

[4]  A. Ho,et al.  Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. , 2020, Cancer.

[5]  D. Nam,et al.  Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient , 2020, Genome Medicine.

[6]  M. Gut,et al.  Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma , 2020, Scientific Reports.

[7]  C. Der,et al.  RAS, wanted dead or alive: Advances in targeting RAS mutant cancers , 2020, Science Signaling.

[8]  J. Khan,et al.  CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG , 2020, Nature Communications.

[9]  Chao Di,et al.  U1 snRNP regulates cancer cell migration and invasion in vitro , 2020, Nature Communications.

[10]  Sung-Bae Kim,et al.  Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations , 2019, Clinical Trials.

[11]  Huan Yang,et al.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors , 2019, Clinical Cancer Research.

[12]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[13]  N. Socci,et al.  Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. , 2018, Cancer Research.

[14]  B. Neel,et al.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.

[15]  J. Khan,et al.  Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute. , 2018 .

[16]  James M. McFarland,et al.  Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2 , 2018, Nature Medicine.

[17]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[18]  N. Ishimaru,et al.  The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells , 2018, Molecular Cancer.

[19]  Anang A. Shelat,et al.  Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.

[20]  Jin Huang,et al.  New tricks for human farnesyltransferase inhibitor: cancer and beyond. , 2017, MedChemComm.

[21]  V. Sukhatme,et al.  Low‐Dose Farnesyltransferase Inhibitor Suppresses HIF‐1α and Snail Expression in Triple‐Negative Breast Cancer MDA‐MB‐231 Cells In Vitro , 2017, Journal of cellular physiology.

[22]  James R. Anderson,et al.  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Schultz,et al.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer , 2016, Clinical Cancer Research.

[24]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[25]  C. Der,et al.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? , 2015, Clinical Cancer Research.

[26]  M. Loh,et al.  Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group , 2015, Pediatric blood & cancer.

[27]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[28]  S. Steinberg,et al.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. , 2014, Neuro-oncology.

[29]  A. Oberg,et al.  Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells , 2014, Haematologica.

[30]  Heather L. Mulder,et al.  Targeting oxidative stress in embryonal rhabdomyosarcoma. , 2013, Cancer cell.

[31]  R. Hills,et al.  The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML , 2012, British journal of haematology.

[32]  E. Perez,et al.  A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103) , 2012, Breast Cancer Research and Treatment.

[33]  L. Borsu,et al.  Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways , 2011, Clinical Cancer Research.

[34]  S. Kaufmann,et al.  Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. , 2011, Blood.

[35]  S. Sebti,et al.  Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.

[36]  M. Prados,et al.  Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. , 2011, Neuro-oncology.

[37]  R. Arceci,et al.  Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group , 2011, Pediatric blood & cancer.

[38]  R. Friedman,et al.  H-ras localizes to cell nuclei and varies with the cell cycle. , 2011, Genes & cancer.

[39]  James R. Anderson,et al.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Merajver,et al.  Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer , 2009, Clinical Cancer Research.

[41]  J. Sparano,et al.  Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  William Pao,et al.  Genetic predictors of MEK dependence in non-small cell lung cancer. , 2008, Cancer research.

[43]  T. T. Baba,et al.  Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway , 2008, Journal of Muscle Research and Cell Motility.

[44]  A. Hall,et al.  Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. , 2008, Cancer research.

[45]  B. Smith,et al.  Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features , 2008, Clinical Cancer Research.

[46]  W. Jędrzejczak,et al.  A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. , 2007, Blood.

[47]  Susan M. Chang,et al.  Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Arceci,et al.  Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  W. Scheithauer,et al.  Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Yixin Wang,et al.  Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia , 2004, BMC Cancer.

[51]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Kurzrock,et al.  Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. , 2003, Blood.

[53]  C. Der,et al.  Ras Family Signaling: Therapeutic Targeting , 2002, Cancer biology & therapy.

[54]  S. Sebti,et al.  Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues , 2000, Expert opinion on investigational drugs.

[55]  C. Bowden,et al.  Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  E K Rowinsky,et al.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  G. Prendergast,et al.  Non-Ras targets of farnesyltransferase inhibitors: focus on Rho , 1998, Oncogene.

[58]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[59]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[60]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[61]  C. Der,et al.  Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity. , 1991, Cancer cells.

[62]  P. Casey,et al.  p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[64]  Eugenio Santos,et al.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene , 1982, Nature.

[65]  Cori Bargmann,et al.  Mechanism of activation of a human oncogene , 1982, Nature.

[66]  A. Ho,et al.  Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations , 2018 .

[67]  R. Firtel,et al.  Spatiotemporal regulation of Ras-GTPases during chemotaxis. , 2009, Methods in molecular biology.

[68]  A. Cox,et al.  Using inhibitors of prenylation to block localization and transforming activity. , 2006, Methods in enzymology.

[69]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[70]  J. Węsierska‐Gądek,et al.  Nuclear Ras: Unexpected subcellular distribution of oncogenic forms , 2001, Journal of cellular biochemistry. Supplement.